Glomerulonephritis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Glomerulonephritis - Pipeline Review, H1 2016', provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis - The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects - The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Glomerulonephritis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Glomerulonephritis Overview 9 Therapeutics Development 10 Pipeline Products for Glomerulonephritis - Overview 10 Pipeline Products for Glomerulonephritis - Comparative Analysis 11 Glomerulonephritis - Therapeutics under Development by Companies 12 Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes 14 Glomerulonephritis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Glomerulonephritis - Products under Development by Companies 18 Glomerulonephritis - Products under Investigation by Universities/Institutes 20 Glomerulonephritis - Companies Involved in Therapeutics Development 21 Alexion Pharmaceuticals, Inc. 21 Amyndas Pharmaceuticals LLC 22 Anthera Pharmaceuticals
List of Tables
Number of Products under Development for Glomerulonephritis, H1 2016 10 Number of Products under Development for Glomerulonephritis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Glomerulonephritis - Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 21 Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 22 Glomerulonephritis - Pipeline by Anthera Pharmaceuticals
List of Figures
Number of Products under Development for Glomerulonephritis, H1 2016 10 Number of Products under Development for Glomerulonephritis - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 41 Number of Products by Top 10 Targets, H1 2016 43 Number of Products by Stage and Top 10 Targets, H1 2016 43 Number of Products by Top 10 Mechanism of Actions, H1 2016 45 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45 Number of Products by Routes of Administration, H1 2016 47 Number of Products by Stage and Routes of Administration, H1 2016 47 Number of Products by Molecule Types, H1 2016 49 Number of Products by Stage and Molecule Types, H1 2016 49
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.